Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00544440
Other study ID # CR016906
Secondary ID COU-AA-BMA
Status Completed
Phase Phase 2
First received October 15, 2007
Last updated July 3, 2014
Start date October 2007
Est. completion date August 2012

Study information

Verified date July 2014
Source Janssen Research & Development, LLC
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the effect of abiraterone acetate on levels of androgens and steroid metabolites in bone marrow plasma of patients with metastatic castration-resistant prostate cancer (CRPC).


Description:

This is a single-center, open-label (identity of assigned study drug will be known) study investigating the effect of abiraterone acetate on levels of testosterone and dihydrotestosterone (DHT) in bone marrow plasma of patients with metastatic CRPC and evaluating the difference in bone marrow androgen levels between patients with and without serum prostate specific antigen (PSA) decline. Approximately 60 medically or surgically castrated male patients with metastatic CRPC will be enrolled. The study will consist of screening, treatment, and follow-up periods. Patients will be treated orally (by mouth) with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression. Follow-up will continue until the patient dies, is lost to follow-up or withdraws informed consent. Bone marrow aspirates will be collected at Week 1 (predose), Week 9, and the final study visit. Safety will be monitored throughout the study.


Recruitment information / eligibility

Status Completed
Enrollment 57
Est. completion date August 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically proven adenocarcinoma of the prostate

- Eastern Cooperative Oncology Group (ECOG) performance status <=2 (Karnofsky Performance Status >=50%)

- Serum testosterone levels <50ng/ml

- Ongoing gonadal androgen deprivation therapy with luteinizing hormone-releasing hormone (LHRH) analogues or orchiectomy (patients, who have not had an orchiectomy, must be maintained on effective LHRH analogue therapy for the duration of the study)

- Progression of disease despite androgen ablation (either documented osseous or soft tissue metastatic disease progression or by prostate specific antigen [PSA] criteria progression)

- Progressive disease is defined by PSA evidence (PSA level of at least 5 ng/ml which has risen on at least 2 successive occasions, at least 2 weeks apart)

- Presence of metastatic bone disease

- Discontinue diethylstilbestrol or steroids treatment for >=4 weeks and for antiandrogens >6 weeks

- Antiandrogen withdrawal: patients who are receiving an antiandrogen as part of primary androgen ablation must demonstrate disease progression following discontinuation of antiandrogen (disease progression after antiandrogen withdrawal is defined as 2 consecutive rising PSA values, obtained at least 2 weeks apart, or documented osseous or soft tissue progression)

- For patients receiving flutamide, at least one of the PSA values must be obtained 4 weeks or more after flutamide discontinuation

- For patients receiving bicalutamide or nilutamide, at least one of the PSA values must be obtained 6 weeks or more after antiandrogen discontinuation

- Adequate adrenal function

- Laboratory values within protocol -defined parameters

- No evidence of chronic or acute disseminated intravascular coagulation or bleeding tendency and no angina at rest

- Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

- Histologic variants other than adenocarcinoma in the primary tumor

- More then 2 different prior chemotherapeutic regimens for metastatic prostate cancer

- Abnormal liver function

- Therapy with other hormonal therapy, including any dose of megestrol acetate (Megace), Ketoconazole, finasteride (Proscar), dutasteride (Avodart) any herbal product known to decrease PSA levels (eg, Saw Palmetto and PC-SPES), or any systemic corticosteroid within 4 weeks prior to first dose of study drug

- Active infection or intercurrent illness that are not controlled

- Unstable angina, myocardial infarction within the previous 6 months, or use of ongoing maintenance therapy for life-threatening ventricular arrhythmia, uncontrolled hypertension, New York Heart Association (NYHA) Class III or IV congestive heart failure

- Prior radiation therapy completed <4 weeks or single fraction of palliative radiotherapy within 14 days prior to first dose of study drug

- Any currently active second malignancy, other than non-melanoma skin cancer

- Active psychiatric illnesses/social situations that would limit compliance with protocol requirements

- Active or uncontrolled autoimmune disease that may require corticosteroid therapy during study

- Severely compromised immunological state, including being positive for the human immunodeficiency virus (HIV)

- Acute or chronic hepatitis B or C

- Initiation of bisphosphonate therapy within 4 weeks prior to first dose of study drug

- Long QT syndrome or bundle branch block or hemiblock or other history of life-threatening arrhythmia (unless the patient has been effectively treated for it and is considered stable)

- Known brain metastasis

- History of pituitary or adrenal dysfunction

- History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug

- Prior therapy with abiraterone acetate

- Any acute toxicities due to prior chemotherapy and/or radiotherapy that have not resolved to a NCI CTCAE (version 3) grade of <=1

- Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Abiraterone acetate
Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
Prednisone
Prednisone 5 mg tablet taken orally twice daily

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Janssen Research & Development, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Detectable Bone Marrow Testosterone Level (>1 Picograms/Mililiter) Baseline (predose Week 1 Day 1) and Week 8 No
Primary Number of Participants With Detectable Bone Marrow Dihydrotestosterone (DHT) Level (>9 Picograms/Mililiter) Baseline (predose Week 1 Day 1) and Week 8 No
Primary Difference in Bone Marrow Testosterone Levels Between Participants With and Without Serum Prostate Specific Antigen Decline Week 8 No
Secondary Number of Participants With Change in Markers of Bone Metabolism Week 8 No
See also
  Status Clinical Trial Phase
Completed NCT00970203 - Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer Phase 2
Completed NCT01400555 - A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1
Terminated NCT03685591 - PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Phase 1
Completed NCT00643617 - CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry N/A
Recruiting NCT01581749 - Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer Phase 4
Completed NCT01424930 - A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT01228760 - A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer Phase 1
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Suspended NCT02759744 - Fusion Guided Focal Laser Ablation of Prostate Cancer N/A
Completed NCT00474383 - An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Phase 2
Completed NCT01284920 - A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients Phase 1/Phase 2
Completed NCT02319239 - Prostate Cancer Stereotactic Radiotherapy N/A
Completed NCT00910754 - A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1
Completed NCT00972309 - A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer Phase 1
Terminated NCT03531827 - Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment Phase 2
Completed NCT00167648 - Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer Phase 2
Not yet recruiting NCT05577689 - Novel Therapy Target in Metastatic Prostate Cancer
Enrolling by invitation NCT03173924 - 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer Phase 2
Completed NCT04703543 - Evaluating the Role of Both PSMA and 64Cu-PET/CT Total Body in Patients With Locally Relapsed Prostate Cancer N/A
Completed NCT01477749 - Sipuleucel-T Manufacturing Demonstration Study Phase 2